Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-453 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7518.091 | 0.9613 | 0.9518 | 1.6174 | |
| MDA-MB-453 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7518.091 | 0.9523 | 0.9405 | 1.6174 | |
| MDA-MB-453 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7518.091 | 0.8762 | 0.8430 | 1.6174 | |
| MDA-MB-453 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7518.091 | 0.8049 | 0.7489 | 1.6174 | |
| MDA-MB-453 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7518.091 | 0.2855 | -0.0787 | 1.6174 | |
| MDA-MB-453 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7518.091 | 0.0091 | -0.8906 | 1.6174 | |
| MDA-MB-453 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7518.091 | 0.0060 | -0.9155 | 1.6174 | |
| MX1 | Unknown | Unknown | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7523.091 | 0.9683 | 0.9317 | 0.9283 | |
| MX1 | Unknown | Unknown | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7523.091 | 0.9624 | 0.9192 | 0.9283 | |
| MX1 | Unknown | Unknown | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7523.091 | 0.9678 | 0.9308 | 0.9283 | |
| MX1 | Unknown | Unknown | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7523.091 | 0.9546 | 0.9024 | 0.9283 | |
| MX1 | Unknown | Unknown | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7523.091 | 0.9666 | 0.9281 | 0.9283 | |
| MX1 | Unknown | Unknown | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7523.091 | 0.8979 | 0.7810 | 0.9283 | |
| MX1 | Unknown | Unknown | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7523.091 | 0.7679 | 0.5048 | 0.9283 | |
| MX1 | Unknown | Unknown | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7523.091 | 0.0150 | -0.9783 | 0.9283 | |
| MX1 | Unknown | Unknown | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7523.091 | 0.0046 | -0.9939 | 0.9283 | |
| SK-BR-3 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7526.091 | 0.9362 | 0.9227 | 1.6709 | |
| SK-BR-3 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7526.091 | 0.9285 | 0.9132 | 1.6709 | |
| SK-BR-3 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7526.091 | 0.9578 | 0.9491 | 1.6709 | |
| SK-BR-3 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7526.091 | 0.9210 | 0.9039 | 1.6709 | |
| SK-BR-3 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7526.091 | 0.9347 | 0.9208 | 1.6709 | |
| SK-BR-3 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7526.091 | 0.8945 | 0.8709 | 1.6709 | |
| SK-BR-3 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7526.091 | 0.6797 | 0.5874 | 1.6709 | |
| SK-BR-3 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7526.091 | 0.0279 | -0.7651 | 1.6709 | |
| SK-BR-3 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7526.091 | 0.0078 | -0.8908 | 1.6709 |